Citicoline supplement sales will expand through 2036, with CDP choline holding a 68.0% share in 2026 as the leading product segment. The market is expected to reach USD 648.0 million in 2026 and USD 1399.0 million by 2036, creating an absolute dollar opportunity of USD 751.0 million between 2026 and 2036.